Gregory L. Beatty

Dr. Gregory L. Beatty is a Professor of Medicine in the Hematology-Oncology division at the Perelman School of Medicine, University of Pennsylvania. He serves as Director of Clinical and Translational Research at the Penn Pancreatic Cancer Research Center and practices at the Abramson Cancer Center. Dr. Beatty is an internationally renowned expert in cancer immunotherapy with a specific focus on pancreatic cancer and glioblastoma.

Dr. Beatty's research centers on developing novel immunotherapies for solid tumors, particularly pancreatic cancer. His work spans CAR-T cell therapy, tumor microenvironment interactions, immune evasion mechanisms, and strategies to overcome immunotherapy resistance. He has pioneered several first-in-human treatment strategies, including mesothelin-targeted CAR T cells and CD40 agonist approaches that alter tumor stroma.

Analysis of Dr. Beatty's publication record (2011-2020) reveals a consistent focus on translating basic immunological discoveries into clinical applications for pancreatic cancer. His work demonstrates progression from preclinical models to human trials, with particular emphasis on overcoming the immunosuppressive tumor microenvironment that characterizes pancreatic cancer. Key themes include T cell therapy, macrophage modulation, and combination approaches targeting multiple resistance mechanisms simultaneously.

Dr. Beatty has led multiple phase 1 clinical trials, including studies of mesothelin-specific CAR T cells and CD40 monoclonal antibodies in combination with standard therapies. His research has demonstrated how immunotherapies can be engineered to overcome specific resistance mechanisms in pancreatic cancer, including T cell exclusion from tumors and the 'don't eat me' signals that protect cancer cells from immune attack.

As Director of Clinical and Translational Research at the Penn Pancreatic Cancer Research Center, Dr. Beatty oversees a robust research program that bridges laboratory discoveries with patient care. His work has established important proof-of-concept for immunotherapy approaches in traditionally immunotherapy-resistant cancers, opening new avenues for treatment of pancreatic cancer.